mresvia - Search News

News

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.

· 3d · on MSN

FDA expands approval of Moderna's RSV vaccine to some adults under age 60

· 3d

FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59

3don MSN

Moderna falls on doubts over new CDC panel's backing of RSV vaccine

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

26d

Moderna Pulls FDA Application for Flu-Covid Combo Vaccine

Moderna has withdrawn its pending application for a combination vaccine for both the flu and Covid-19, saying it will resubmit later this year once it has more data.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA

Trending now